Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients

Journal of Gastrointestinal Cancer

Volumn 43, Issue 3, 2012, Pages 444-455

  Wang, Jayson ^a   Hollingshead, James ^a   El Masry, Nabil ^b   Horncastle, Donna ^a   Talbot, Ian ^c   Tomlinson, Ian ^d   Alison, Malcolm R ^e   El Bahrawy, Mona ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c ST MARK S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adenoma; Colon; EGFR; FAP; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ARTICLE; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOMA; COLON MUCOSA; CONTROLLED STUDY; CYTOPLASM; FAMILIAL COLON POLYPOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; ADENOMA; ADENOMATOUS POLYPOSIS COLI; COLONIC NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM GRADING; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84866362747     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-011-9330-9     Document Type: Article

References (39)

1. Bulow S. The Danish polyposis register. Description of the methods of detection and evaluation of completeness. Dis Colon Rectum. 1984;27(6):351-5.
2. Bodmer WF et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 1987;328(6131):614-6.
3. Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 2002;38(7):867-71.
4. Debinski HS et al. Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology. 1996;110(4):1028-30.
5. Kopp R et al. Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis Colon Rectum. 2003;46(10):1391-9.
6. Koretz K, Schlag P, Moller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-9.
7. Kapitanovic S et al. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112(4):1103-13.
8. Nathanson DR et al. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer. 2003;105(6):796-802.
9. Treisman R. Ternary complex factors: growth factor regulated transcriptional activators. Curr Opin Genet Dev. 1994;4(1):96-101.
10. Chang F, Steelman LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle. 2002;1(3):220-6.
11. Malumbres M et al. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15 (INK4b). Mol Cell Biol. 2000;20(8):2915-25.
12. Ostrowski J et al. Increased constitutive activity of mitogenactivated protein kinase and renaturable 85 kDa kinase in humancolorectal cancer. Br J Cancer. 1998;78(10):1301-6.
13. Park KS et al. Differential regulation of MAP kinase cascade in human colorectal tumorigenesis. Br J Cancer. 1999;81(7):1116-21.
14. Yasui W. et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988;48(1):137-41.
15. Kruszewski WJ, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 29(5):207-12.
16. Lee SH et al. Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS. 2004;112(4-5):233-8.
17. Vicent S et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004;90(5):1047-52.
18. Baba Y, et al. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010;103(7):1025-33.
19. Lee JC et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer. 2002;38(8):1065-71.
20. Dursun A et al. Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res. 2001;7(1):24-7.
21. Tsioulias GJ et al. erbB-2 gene expression in colorectal cancer. Jpn J Exp Med. 1990;60(6):343-9.
22. D'Emilia J et al. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene. 1989;4(10):1233-9.
23. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94(5):1593-611.
24. Yen LC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg. 2010;251(2):254-60.
25. Hecht JR, et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010;16(7):2205-13.
26. Alferez D et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc (Min/+) mice. Mol Cancer Ther. 2008;7(3):590-8.
27. Bashir O et al. Effect of epidermal growth factor administration on intestinal cell proliferation, crypt fission and polyp formation in multiple intestinal neoplasia (Min) mice. Clin Sci (Lond). 2003;105(3):323-30.
28. Moran AE et al. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6JMin/+ mice. J Biol Chem. 2004;279(41):43261-72.
29. Schmitz KJ et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch. 2007;450(2):151-9.
30. Gulmann C et al. Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol. 2009;218(4):514-9.
31. Attar BM, Atten MJ, Holian O. MAPK activity is down-regulated in human colon adenocarcinoma: correlation with PKC activity. Anticancer Res. 1996;16(1):395-9.
32. Yuen ST et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62(22):6451-5.
33. Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-45.
34. Karapetis CS et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-65.
35. Jiang Y et al. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer. 2009;115(16):3609-17.
36. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009;16(4):196-203.
37. Torrance CJ et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000;6(9):1024-8.
38. Rice PL et al. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res. 2004;64(22):8148-51.
39. Yeh TC et al. Biological characterization of ARRY-142886(AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576-83.